Go Pro
→ A Simple Guide to Options Trading While It's Still Free (From True Market Insiders) (Ad)tc pixel Free INBS Stock Alerts

Intelligent Bio Solutions (INBS) Competitors

Intelligent Bio Solutions logo
$2.30 -0.17 (-6.88%)
As of 09/3/2026 04:00 PM Eastern
Compare

INBS vs. FEMY, BEAT, PETV, LFWD, and CTSO

Should you buy Intelligent Bio Solutions stock or one of its competitors? Intelligent Bio Solutions's main competitors and comparable companies include Femasys (FEMY), HeartBeam (BEAT), PetVivo (PETV), Lifeward (LFWD), and Cytosorbents (CTSO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Intelligent Bio Solutions compare to Femasys?

Femasys (NASDAQ:FEMY) and Intelligent Bio Solutions (NASDAQ:INBS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

65.3% of Femasys shares are owned by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are owned by institutional investors. 7.8% of Femasys shares are owned by company insiders. Comparatively, 1.3% of Intelligent Bio Solutions shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Femasys currently has a consensus target price of $50.00, indicating a potential upside of 1,533.99%. Given Femasys' stronger consensus rating and higher possible upside, equities research analysts clearly believe Femasys is more favorable than Intelligent Bio Solutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Femasys
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Intelligent Bio Solutions
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Femasys has a beta of -2.07, meaning that its share price is 307% less volatile than the broader market. Comparatively, Intelligent Bio Solutions has a beta of 4.25, meaning that its share price is 325% more volatile than the broader market.

In the previous week, Intelligent Bio Solutions had 3 more articles in the media than Femasys. MarketBeat recorded 3 mentions for Intelligent Bio Solutions and 0 mentions for Femasys. Intelligent Bio Solutions' average media sentiment score of 0.31 beat Femasys' score of 0.00 indicating that Intelligent Bio Solutions is being referred to more favorably in the news media.

Company Overall Sentiment
Femasys Neutral
Intelligent Bio Solutions Neutral

Intelligent Bio Solutions has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Intelligent Bio Solutions, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Femasys$2.29M11.20-$18.63M-$3.53N/A
Intelligent Bio Solutions$4.22M1.65-$12.43M-$9.02N/A

Intelligent Bio Solutions has a net margin of -294.88% compared to Femasys' net margin of -534.36%. Intelligent Bio Solutions' return on equity of -175.35% beat Femasys' return on equity.

Company Net Margins Return on Equity Return on Assets
Femasys-534.36% -225.97% -74.68%
Intelligent Bio Solutions -294.88%-175.35%-91.25%

Summary

Femasys and Intelligent Bio Solutions tied by winning 8 of the 16 factors compared between the two stocks.

How does Intelligent Bio Solutions compare to HeartBeam?

Intelligent Bio Solutions (NASDAQ:INBS) and HeartBeam (NASDAQ:BEAT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

33.0% of Intelligent Bio Solutions shares are owned by institutional investors. Comparatively, 7.8% of HeartBeam shares are owned by institutional investors. 1.3% of Intelligent Bio Solutions shares are owned by company insiders. Comparatively, 18.0% of HeartBeam shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

HeartBeam has a net margin of 0.00% compared to Intelligent Bio Solutions' net margin of -294.88%. Intelligent Bio Solutions' return on equity of -175.35% beat HeartBeam's return on equity.

Company Net Margins Return on Equity Return on Assets
Intelligent Bio Solutions-294.88% -175.35% -91.25%
HeartBeam N/A -686.78%-348.65%

Intelligent Bio Solutions has a beta of 4.25, suggesting that its share price is 325% more volatile than the broader market. Comparatively, HeartBeam has a beta of -0.8, suggesting that its share price is 180% less volatile than the broader market.

HeartBeam has a consensus price target of $4.00, indicating a potential upside of 852.15%. Given HeartBeam's stronger consensus rating and higher possible upside, analysts plainly believe HeartBeam is more favorable than Intelligent Bio Solutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intelligent Bio Solutions
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
HeartBeam
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.67

Intelligent Bio Solutions has higher revenue and earnings than HeartBeam. HeartBeam is trading at a lower price-to-earnings ratio than Intelligent Bio Solutions, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intelligent Bio Solutions$4.22M1.65-$12.43M-$9.02N/A
HeartBeamN/AN/A-$21.01M-$0.51N/A

In the previous week, Intelligent Bio Solutions had 3 more articles in the media than HeartBeam. MarketBeat recorded 3 mentions for Intelligent Bio Solutions and 0 mentions for HeartBeam. Intelligent Bio Solutions' average media sentiment score of 0.31 beat HeartBeam's score of 0.00 indicating that Intelligent Bio Solutions is being referred to more favorably in the media.

Company Overall Sentiment
Intelligent Bio Solutions Neutral
HeartBeam Neutral

Summary

Intelligent Bio Solutions beats HeartBeam on 9 of the 16 factors compared between the two stocks.

How does Intelligent Bio Solutions compare to PetVivo?

PetVivo (NASDAQ:PETV) and Intelligent Bio Solutions (NASDAQ:INBS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

24.5% of PetVivo shares are held by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are held by institutional investors. 10.8% of PetVivo shares are held by company insiders. Comparatively, 1.3% of Intelligent Bio Solutions shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Intelligent Bio Solutions had 2 more articles in the media than PetVivo. MarketBeat recorded 3 mentions for Intelligent Bio Solutions and 1 mentions for PetVivo. Intelligent Bio Solutions' average media sentiment score of 0.31 beat PetVivo's score of 0.00 indicating that Intelligent Bio Solutions is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PetVivo
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Intelligent Bio Solutions
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PetVivo
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Intelligent Bio Solutions
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

PetVivo has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market. Comparatively, Intelligent Bio Solutions has a beta of 4.25, suggesting that its share price is 325% more volatile than the broader market.

Intelligent Bio Solutions has a net margin of -294.88% compared to PetVivo's net margin of -902.82%. Intelligent Bio Solutions' return on equity of -175.35% beat PetVivo's return on equity.

Company Net Margins Return on Equity Return on Assets
PetVivo-902.82% -4,813.07% -281.78%
Intelligent Bio Solutions -294.88%-175.35%-91.25%

PetVivo has higher earnings, but lower revenue than Intelligent Bio Solutions. PetVivo is trading at a lower price-to-earnings ratio than Intelligent Bio Solutions, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PetVivo$1.05M24.53-$10.95M-$0.34N/A
Intelligent Bio Solutions$4.22M1.65-$12.43M-$9.02N/A

Summary

Intelligent Bio Solutions beats PetVivo on 10 of the 14 factors compared between the two stocks.

How does Intelligent Bio Solutions compare to Lifeward?

Lifeward (NASDAQ:LFWD) and Intelligent Bio Solutions (NASDAQ:INBS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Lifeward has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Intelligent Bio Solutions has a beta of 4.25, meaning that its stock price is 325% more volatile than the broader market.

Lifeward presently has a consensus price target of $10.00, suggesting a potential upside of 40.85%. Given Lifeward's stronger consensus rating and higher probable upside, analysts plainly believe Lifeward is more favorable than Intelligent Bio Solutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lifeward
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Intelligent Bio Solutions
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

In the previous week, Lifeward had 1 more articles in the media than Intelligent Bio Solutions. MarketBeat recorded 4 mentions for Lifeward and 3 mentions for Intelligent Bio Solutions. Intelligent Bio Solutions' average media sentiment score of 0.31 beat Lifeward's score of 0.10 indicating that Intelligent Bio Solutions is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lifeward
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Intelligent Bio Solutions
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Intelligent Bio Solutions has lower revenue, but higher earnings than Lifeward. Lifeward is trading at a lower price-to-earnings ratio than Intelligent Bio Solutions, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lifeward$22.03M0.91-$19.91M-$16.82N/A
Intelligent Bio Solutions$4.22M1.65-$12.43M-$9.02N/A

26.8% of Lifeward shares are owned by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are owned by institutional investors. 1.5% of Lifeward shares are owned by insiders. Comparatively, 1.3% of Intelligent Bio Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Lifeward has a net margin of -141.28% compared to Intelligent Bio Solutions' net margin of -294.88%. Intelligent Bio Solutions' return on equity of -175.35% beat Lifeward's return on equity.

Company Net Margins Return on Equity Return on Assets
Lifeward-141.28% -235.86% -81.72%
Intelligent Bio Solutions -294.88%-175.35%-91.25%

Summary

Lifeward and Intelligent Bio Solutions tied by winning 8 of the 16 factors compared between the two stocks.

How does Intelligent Bio Solutions compare to Cytosorbents?

Cytosorbents (NASDAQ:CTSO) and Intelligent Bio Solutions (NASDAQ:INBS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Cytosorbents has a net margin of -48.94% compared to Intelligent Bio Solutions' net margin of -294.88%. Intelligent Bio Solutions' return on equity of -175.35% beat Cytosorbents' return on equity.

Company Net Margins Return on Equity Return on Assets
Cytosorbents-48.94% -431.65% -41.94%
Intelligent Bio Solutions -294.88%-175.35%-91.25%

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are owned by institutional investors. 7.8% of Cytosorbents shares are owned by company insiders. Comparatively, 1.3% of Intelligent Bio Solutions shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cytosorbents has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market. Comparatively, Intelligent Bio Solutions has a beta of 4.25, meaning that its share price is 325% more volatile than the broader market.

In the previous week, Cytosorbents had 2 more articles in the media than Intelligent Bio Solutions. MarketBeat recorded 5 mentions for Cytosorbents and 3 mentions for Intelligent Bio Solutions. Intelligent Bio Solutions' average media sentiment score of 0.31 beat Cytosorbents' score of -0.10 indicating that Intelligent Bio Solutions is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cytosorbents
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Intelligent Bio Solutions
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cytosorbents currently has a consensus target price of $5.38, indicating a potential upside of 1,435.71%. Given Cytosorbents' stronger consensus rating and higher probable upside, equities analysts plainly believe Cytosorbents is more favorable than Intelligent Bio Solutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytosorbents
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Intelligent Bio Solutions
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Cytosorbents has higher revenue and earnings than Intelligent Bio Solutions. Cytosorbents is trading at a lower price-to-earnings ratio than Intelligent Bio Solutions, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytosorbents$37.06M0.59-$8.20M-$0.29N/A
Intelligent Bio Solutions$4.22M1.65-$12.43M-$9.02N/A

Summary

Cytosorbents beats Intelligent Bio Solutions on 10 of the 16 factors compared between the two stocks.

Get Intelligent Bio Solutions News Delivered to You Automatically

Sign up to receive the latest news and ratings for INBS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INBS vs. The Competition

Export
MetricIntelligent Bio SolutionsHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$7.48M$5.81B$7.26B$12.73B
Dividend YieldN/A1.76%2.53%8.86%
P/E Ratio-0.2525.93273.2825.38
Price / Sales1.6573.29613.4892.60
Price / CashN/A33.1477.8252.26
Price / Book1.316.0412.896.14
Net Income-$12.43M$150.03M$3.47B$349.01M
7 Day Performance-2.54%-1.30%0.61%-0.27%
1 Month Performance27.07%1.29%5.73%0.68%
1 Year Performance-84.87%9.89%25.37%14.84%

Intelligent Bio Solutions Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INBS
Intelligent Bio Solutions
0.9811 of 5 stars		$2.30
-6.9%		N/A-85.4%$7.48M$4.22MN/A10
FEMY
Femasys
2.9126 of 5 stars		$3.26
-5.0%		$50.00
+1,433.7%		-58.6%$28.73M$2.29MN/A30
BEAT
HeartBeam
1.8057 of 5 stars		$0.45
-3.3%		$4.00
+779.7%		-70.2%$26.48MN/AN/A1,700
PETV
PetVivo
N/A$0.68
flat		N/A-15.5%$25.81M$1.05MN/A20
LFWD
Lifeward
2.2982 of 5 stars		$7.20
-5.9%		$10.00
+38.9%		+3.7%$21.67M$21.82MN/A60

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:INBS) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Buy this stock tomorrow morning
A new strategy called Sell This, Buy That aims to help investors rotate out of overpriced AI stocks before a p...
Chaikin Analytics | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel